The Swiss Group for Clinical Cancer Research (SAKK) has announced that the patient recruitment of the phase II trial of lurbinectedin as a single-agent for the treatment of patients with progressive malignant pleural mesothelioma has been completed.
This trial is being carried out by SAKK in collaboration with PharmaMar. It is a single-arm, multicenter Phase II trial involving 42 patients for the treatment of progressive malignant pleural mesothelioma. The primary endpoint of the study is progression-free survival (PFS) at 12 weeks and these results are expected early in 2019.
According to Dr. Yannis Metaxas, coordinating investigator of this trial: "Patient recruitment has been very rapid, far faster than we expected. From what we have been able to observe so far, we hope to get first results in the first few months of 2019.”
Malignant pleural mesothelioma is a rare tumor that arises from the mesothelial cells of the pleural, peritoneal, or pericardial lining, and is often associated with asbestos exposure, usually with a very poor prognosis at the time of diagnosis. There is no cure for most malignant mesotheliomas, the goal of current cancer treatments (surgery, radiation therapy, and chemotherapy) is to reduce or eliminate symptoms as well as prolong progression-free survival (PFS) and/or overall survival (OS). There is currently no standard treatment for progressive disease.